DOCSLIB.ORG

Formation of Iodinated Disinfection By-Products From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Formation of Iodinated Disinfection By-Products From FORMATION OF IODINATED DISINFECTION BY-PRODUCTS FROM IODINATED X-RAY CONTRAST MEDIA, IOPAMIDOL, IN THE PRESENCE OF NOM AND CHLORINATED OXIDANTS. A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfilment of the Requirements for the Degree Master of Science Elizabeth Ann Crafton December, 2014 FORMATION OF IODINATED DISINFECTION BY-PRODUCTS FROM IODINATED X-RAY CONTRAST MEDIA, IOPAMIDOL, IN THE PRESENCE OF NOM AND CHLORINATED OXIDANTS. Elizabeth Ann Crafton Thesis Approved: Accepted: ____________________________ ____________________________ Advisor Department Chair Dr. Stephen E. Duirk Dr. Wieslaw Binienda _____________________________ ____________________________ Committee member Dean of the College Dr. Teresa J. Cutright Dr. George K. Haritos _____________________________ ____________________________ Committee member Interim Dean of Graduate School Dr. Lan Zhang Dr. Rex Ramsier ____________________________ Date ii ABSTRACT The objective of this study was to investigate the formation of iodinated disinfection by-products (iodo-DBPs) where iodinated x-ray contrast media (ICM), Iopamidol, acted as source of iodine, with respect to pH (6.5, 7.5, 8.5 and 9.0) in the presence of natural organic matter (NOM) and chlorinated oxidant. This was achieved by varying the NOM concentration as well as iopamidol concentrations. Iodinated trihalomethane (iodo-THM) formation was highest at pH 9.0 for chlorine and at pH 6.5 for monochloramine. A considerable increase in formation was observed from pH 6.5 to 7.5 and from 8.5 to 9.0 with respect to chlorine as oxidant. Monochloramine expressed a decreasing trend from pH 6.5 to 9.0. The most predominately formed iodo-THM was dichloroiodomethane, 57.5 nM for chlorine at pH 9.0 (DOC = 2.51 mg/L-L) and 35.2 nM for monochloramine at pH 6.5 (DOC = 2.51 mg/L-L). Chloroform formation was also impacted by the introduction of iopamidol to reactor. Monochloramine produced a wider variety of iodo-DBPs at lower concentrations in comparison to chlorine. Variation of NOM proved to impact the formation of iodo-DBPs. When NOM levels were reduced to a quarter of the original capacity (2.51 – 0.63 mg/L-L) dichloroiodomethane formation doubled at pH 9.0 with respect to chlorine (110.5 nM). Monochloramine expressed a decreasing trend with respect to decreasing levels of NOM with the source water. For both oxidants, half and quarter capacity of NOM, 1.26 and 0.63 mg/L-L respectively, expressed considerably similar formation. iii Additionally, two-way analysis of variance (two way-ANOVA) tables were generated for two response variables, chloroform and dichloroiodomethane. With respect to each oxidant, iopamidol and pH were evaluated while NOM level remained constant and NOM and pH were evaluated while iopamidol remained constant. In regard to chloroform as the response variable with varied DOC, significance was yielded for both DOC (p-value of 0.0004) and pH (p-value of 0.0325) with respect to monochloramine: whereas chlorine only exhibited significance in regard to pH (p- value of 0.0052). Varied iopamidol expressed significance for both iopamidol (p- value of < 0.0001) and pH (p-value of 0.0014) with respect to monochloramine. In regard to chlorine, significance was only determined for pH (p-value of < 0.0001). With respect to dichloroiodomethane acting as the response variable amongst varied DOC, significance was determined in regard to pH for both chlorine (p-value of 0.0009) and monochloramine (p-value of 0.0012). Varied iopamidol concentration, significance was found for iopamidol for chlorine (p-value of 0.0064) and pH for monochloramine (p-value of 0.0029). While the findings of said statistical analysis were in most cases significant, considering the interaction plots and the lack of parallelism expressed, one can assume interaction between independent variables (i.e. factors). While it cannot be determined if the lack of parallelism is due to randomness or interaction, past work supports the assumption of interaction over randomness. iv ACKNOWLEDGEMENTS First and foremost, I like to thank my advisor, Dr. Stephen Duirk for numerous years of support and guidance. I would also like to thank Dr. Teresa Cutright for her continued inspiration and mentorship. I would like to thank my committee for their support throughout this work and their input, Dr. Stephen Duirk, Dr, Teresa Cutright and Dr. Lan Zhang. I would like to thank my friends/peers: Edward Machek, Nana Ackerson, Mallory Crow and Alexis Killinger. I would like to express my deepest gratitude for my parents, Jay and Diane Crafton. I would also like to thank both of my sisters, Dr. Sarah Crafton and Rachel Crafton-Stiver, for being impeccable role models whom I can always look to for support and guidance. This work is dedicated to my uncle and fellow research scientist, Dr. John Shainoff. v TABLE OF CONTENTS Page LISTS OF TABLES .................................................................................................... viii LISTS OF FIGURES .................................................................................................. xiv CHAPTER I. INTRODUCTION ...................................................................................................... 1 1.1 Background .......................................................................................................... 1 1.2 Problem Statement ............................................................................................... 6 1.3 Specific Objectives .............................................................................................. 7 II. LITERATURE REVIEW .......................................................................................... 9 2.1 Iodinated X-Ray Contrast Media ......................................................................... 9 2.2 Occurrence of ICM in Water and Wastewater ................................................... 12 2.3 Chemical Oxidation and Disinfection By-Products (DBPs) .............................. 14 2.3.1 Chemical Oxidation .................................................................................... 14 2.3.2 Disinfection By-Product Formation ............................................................ 15 2.3.3 Aqueous Chlorine Reactivity and DBP Formation..................................... 17 2.3.4 Chloraime .................................................................................................... 19 2.4. ICM Transformation and Iodo-DBPs ............................................................... 20 2.4.1 ICM Transformation ................................................................................... 21 2.4.2 Microbial Transformation ........................................................................... 21 2.5 Toxicity .............................................................................................................. 22 vi III. MATERIALS AND METHODS .................................................................................. 27 3.1 Chemicals and Reagents .................................................................................... 27 3.2 Source Water Characterization .......................................................................... 28 3.3 Experimental Methods ....................................................................................... 33 3.3.1 DBP Formation Experiments with Cleveland Source Water ...................... 34 3.4 Analytical Procedures ........................................................................................ 35 3.4.1 Disinfection By-product ............................................................................. 35 3.6 Analyses of DBPs .............................................................................................. 38 IV. RESULTS AND DISCUSSION ............................................................................ 66 4.1 Introduction ........................................................................................................ 66 4.2 Predominant Observed Trends ........................................................................... 67 4.3 Statistical Analysis ........................................................................................... 118 V. CONCLUSIONS AND RECOMMENDATIONS ............................................... 125 5.1 Introduction ...................................................................................................... 125 5.2 Conclusions ...................................................................................................... 126 5.3 Recommendations ............................................................................................ 129 REFERENCES .......................................................................................................... 131 APPENDIX ................................................................................................................ 146 vi i LIST OF TABLES Table Page 3.1: Source water characteristics from Cleveland water .............................................. 29 3.2: Florescence EEM regions proposed by Chen et al. (2003) .................................. 31 3.3: Florescence regions for Cleveland source waters, 1 mg/L C ............................... 31 3.4: Oven temperature programming for THMs and HANs analysis on GC/μECD ... 38 3.5: Oven temperature programming for HAAs analysis on GC/μECD ..................... 39 3.6: Limit of quantification (LOQ) for the detection of DBPs .................................... 65
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • 201277Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201277Orig1s000 OTHER REVIEW(S) PMR/PMC Development Template This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package. PMR/PMC Description: DARRTS Set #1743-1 A study that will examine the safety of Gadavist in new born and neonates animals, following a single dose and limited repeated dose administrations. The study will provide safety data assessing mortality, toxicities, and potential reversibility of observed clinical and histopathological findings. The study will also examine the pharmacokinetics of Gadavist including tissue deposition of Gadolinium. PMR/PMC Schedule Milestones: Final Protocol Submission: May, 2011 Study/Trial Completion: January, 2012 Final Report Submission: June, 2012 Other: 1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe. Unmet need Life-threatening condition Long-term data needed Only feasible to conduct post-approval (I removed this check on the nonclinical form) Prior clinical experience indicates safety Small subpopulation affected (I removed this check on the nonclinical form) Theoretical concern Other Proposed nonclinical study will evaluate the safety of Gadavist in a non clinical animal model prior to clinical exposure in view of known risk of NSF in adults especially those with renal impairment. 2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.” ReferencePMR/PMC ID: 2918081Development Template Last Updated 3/14/2011 Page 1 of 4 To evaluate the safety of Gadavist in newborn and neonate animals.
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • MDCT and Contrast Media: What Are the Risks?
    071_078_00_Thomsen:Thomsen 13-02-2008 9:32 Pagina 71 MDCT and Contrast Media: What are the Risks? Henrik S. Thomsen Department of Diagnostic Radiology, Copenhagen University Hospital Herlev, Herlev Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark Introduction Renal Adverse Reactions With the advent of multi-detector computed to- Contrast-material-induced kidney damage is imme- mography (MDCT) technology, the number of pa- diate, starting as soon as the first CM molecule reach- tients undergoing contrast-enhanced CT (CECT) es the kidney; however, it takes several hours or days studies has steadily grown in the last 6 years. In for a deterioration of renal function to be detected. 2005, approximately 22 million CECT examinations Despite more than 30 years of research, the patho- were carried out in the European Union, and 32 mil- physiology of CM-induced nephropathy (CIN) is lion in the United States (The Imaging Market Guide poorly elucidated. Nonetheless, several risk factors 2005. Arlington Medical Resources, Inc., Philadel- are well-known and can be divided into CM- and pa- phia, PA). Unfortunately, post-contrast-material-re- tient-related factors. lated adverse events, i.e., all those unintended and unfavorable signs, symptoms, or diseases temporally associated with the use of an iodinated contrast ma- Contrast-Medium-Related Factors terial (CM), are a common occurrence in radiology departments. Most adverse events occur within the More than 25 years ago, Barrett and Carlisle [1] first 60 min following CM administration (“imme- showed that the incidence of CIN is significantly diate” or “acute” adverse events), with the greatest higher after the administration of high-osmolarity risk in the first 20 min.
    [Show full text]
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • Reference List Concerning Spinal Adhesive Arachnoiditis
    SPINAL ADHESIVE ARACHNOIDITIS RMA ID Reference List for RMA363-2 as at June 2020 Number Abel TJ, Howard MA 3rd, Menezes A (2014). Syringomyelia and spinal arachnoiditis resulting from aneurysmal subarachnoid hemorrhage: 94310 Report of two cases and review of the literature. J Craniovertebr Junction Spine, 5(1): 47-51. Abhinav K, Bradley M, Aquilina K, et al (2012). Spinal arachnoiditis and 72882 cyst formation with subarachnoid haemorrhage. Br J Neurosurg, 26(4): 574-5. Abouleish E, Vega S, Blendinger I, et al (1975). Long-term follow-up of 94392 epidural blood patch. Anesth Analg, 54(4): 459-63. Agrawal A, Agrawal A, Agrawal C, et al (2006). An unusual spinal 59948 arachnoiditis. Clin Neurol Neurosurg, 108(8): 775-9. Al Maach N, Vogels OJ, Bollen TL, et al (2010). Arachnoiditis and 59949 communicating hydrocephalus as a complication of epidural blood patch. J Neurol, 257(4): 672-3. Aldrete JA (2003). Neurologic deficits and arachnoiditis following 59950 neuroaxial anesthesia. Acta Anaesthesiol Scand, 47(1): 3-12. Aldrete JA (2004). [Comment] Chronic adhesive arachnoiditis. Br J 59947 Anaesth, 93(2): 301; Author reply 301-3. Aldrete JA, Brown TL (1997). [Comment] Intrathecal hematoma and 94322 arachnoiditis after prophylactic blood patch through a catheter. Anesth Analg, 84(1): 233-4. Anderson TL, Morris JM, Wald JT, et al (2017). Imaging appearance of 94311 advanced chronic adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol, 209(3): 648-55. Anim-Somuah M, Smyth R, Howell C (2005). Epidural versus non- 60550 epidural or no analgesia in labour. Cochrane Database Syst Rev, 4: CD000331.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]